Last reviewed 2026-04-19 · How we verify

Erismodegib

At a glance

Approved indications

• Basal cell carcinoma of skin

Common side effects

No common side effects on file.

Key clinical trials

• Phase Ib Study of Single Agent LDE225, an Oral Hedgehog Inhibitor, as Second-Line Therapy in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis (Phase 1)
• An Open-Label Pilot Study to Evaluate the Efficacy and Safety of a Combination Treatment of Sonidegib (LDE225) and Buparlisib (BKM120) For the Treatment of Advanced Basal Cell Carcinomas (Phase 2)
• Phase I Trial of Sonidegib and Pembrolizumab in Advanced Solid Tumors (Phase 1)
• A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer (EARLY/Phase 1)
• A Prospective, Open-Label, Single-Arm, Multi-Center, Phase IV Efficacy and Safety Study of Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China (Phase 4)
• Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT (Phase 1)
• Phase IB Trial of LDE225 and Weekly Paclitaxel in Recurrent Platinum Resistant Ovarian Cancer (Phase 1)
• A Randomized, Double-blind, Vehicle-controlled, Multicenter Trial of Topically Administered LDE225 Cream (0.75% Bid) to Evaluate Clearance of Basal Cell Carcinoma in Adult Patients With Nevoid Basal C (Phase 2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Erismodegib CI brief — competitive landscape report
• Erismodegib updates RSS · CI watch RSS
• Washington University School of Medicine portfolio CI